


21260YP

Page 3

In the Claims:

Claims 1-12 (Canceled)

13. (Currently Amended) A compound of the structural formula I:

Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:

wherein,

R represents hydrogen, or C₁₋₆ alkyl;X represents -(CHR₇)_pCO-;Y represents -CO(CH₂)_n-;

Q represents N;

R_w represents H, C₁₋₆ alkyl, -C(O)C₁₋₆ alkyl, -C(O)OC₁₋₆ alkyl, -SO₂N(R)₂, -SO₂C₁₋₆ alkyl, -SO₂C₆₋₁₀ aryl, NO₂, CN or -CON(R)₂;R₂ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₃₋₈ cycloalkyl, said alkyl, optionally substituted with 1-3 groups selected from R^a;R₃ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₃₋₈ cycloalkyl, said alkyl, optionally substituted with 1-3 groups of R^a;

or, when Q is N, R₂ and R₃ taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;

21260YP

Page 4

R4 and R5 independently represent hydrogen, C1-6 alkoxy, OH, C1-6 alkyl, SO₄C₁₋₆ alkyl, COC₁₋₆ alkyl, COOR, SO₃H, -O(CH₂)_nN(R)₂, -O(CH₂)_nCO₂R, CF₃, OCF₃, -N(R)₂, nitro, cyano, C1-6 alkylamino, or halogen; and

R6 represents hydrogen, C1-10 alkyl, -(CH₂)_nC₆₋₁₀ aryl, NR_cR_d, -NR(CH₂)_nC₆₋₁₀ aryl, -N((CH₂)_nC₆₋₁₀ aryl)₂, -(CH₂)_nC₃₋₁₀ heterocyclyl, -NR(CH₂)_nC₃₋₁₀

PAGE 5/5 * RCVD AT 1/14/2009 11:34:32 AM [Eastern Standard Time] * SVR:USPTO-EFEXRF-4/11 * DNIS:2738300 * CSID:732 594 2250 * DURATION (mm-ss):03-50

BEST AVAILABLE COPY